These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 10087434)

  • 21. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.
    Schmidt ML; Gamerman S; Smith HE; Scott JP; DiMichele DM
    Am J Hematol; 1994 Sep; 47(1):36-40. PubMed ID: 8042614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NovoSeven in immune tolerance therapy.
    Brackmann HH; Effenberger E; Hess L; Schwaab R; Oldenburg J
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S39-44. PubMed ID: 10850563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
    Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
    Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia.
    Morfini M; Bjerre J
    Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
    Faranoush M; Abolghasemi H; Mahboudi F; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
    Clin Appl Thromb Hemost; 2016 Mar; 22(2):184-90. PubMed ID: 25343955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
    Shirahata A; Kamiya T; Takamatsu J; Kojima T; Fukutake K; Arai M; Hanabusa H; Tagami H; Yoshioka A; Shima GM; Naka GH; Fujita GS; Minamoto Y; Kamizono J; Saito H
    Int J Hematol; 2001 Jun; 73(4):517-25. PubMed ID: 11503968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
    Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
    Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
    Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S;
    J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
    Brady KM; Easley RB; Tobias JD
    Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
    Smith OP
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
    Łaguna P; Mital A
    Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
    Bysted BV; Scharling B; Møller T; Hansen BL
    Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
    Rice KM; Savidge GF
    Haemostasis; 1996; 26 Suppl 1():131-4. PubMed ID: 8904187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with activated factor VII: focus on safety aspects.
    Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.
    Kenet G; Martinowitz U
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S38-41. PubMed ID: 18544424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
    Mariani G; Konkle BA; Ingerslev J
    Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.